Production, characterization and pharmacokinetic properties of antibodies with N-linked Mannose-5 glycans

mAbs

Volumn 4, Issue 4, 2012, Pages 475-487

  Yu, Marcella ^a,b   Brown, Darren ^a,c   Reed, Chae ^a   Chung, Shan ^a   Lutman, Jeff ^a   Stefanich, Eric ^a   Wong, Anne ^a   Stephan, Jean Philippe ^a   Bayer, Robert ^a,d  

^a GENENTECH INC   (United States)

^b SANOFI   (France)

^c ILLUMINA INC   (United States)

^d GENOMICS INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION   (United States)

Author keywords

ADCC; Glycosylation; High mannose; Pharmacokinetics; Therapeutic antibody

Indexed keywords

ALPHA MANNOSIDASE; FC RECEPTOR IIA; FC RECEPTOR IIB; KIFUNENSINE; MANNOSIDASE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY MAN5; MONOCLONAL ANTIBODY MAN8; MONOCLONAL ANTIBODY MAN9; OMALIZUMAB; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY PRODUCTION; ANTIBODY TITER; AREA UNDER THE CURVE; ARTICLE; BINDING AFFINITY; CELL CULTURE; CELL GROWTH; CELL VIABILITY; COMPLEMENT DEPENDENT CYTOTOXICITY; CONTROLLED STUDY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; ENZYME ACTIVITY; FEMALE; FUCOSYLATION; GLYCOSYLATION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PHARMACOKINETICS; PROTEIN EXPRESSION; RECEPTOR BINDING; SINGLE DRUG DOSE;

ALKALOIDS; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; AREA UNDER CURVE; BINDING, COMPETITIVE; CELL LINE, TUMOR; CELL SURVIVAL; CELLS, CULTURED; CHO CELLS; CRICETINAE; CRICETULUS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNOGLOBULIN FC FRAGMENTS; MANNOSE; MANNOSIDASES; METABOLIC CLEARANCE RATE; MICE; MICE, NUDE; POLYSACCHARIDES; RECEPTORS, IGG; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION;

EID: 84863440630     PISSN: 19420862     EISSN: 19420870     Source Type: Journal    
DOI: 10.4161/mabs.20737     Document Type: Article

References (39)

1. Jefferis R. Antibody therapeutics: isotype and glycoform selection. Expert Opin Biol Ther 2007; 7:1401-13; PMID:17727329; http://dx.doi.org/10.1517/ 14712598.7.9.1401.
2. Jefferis R. Glycosylation as a strategy to improve antibody-based therapeutics. Nat Rev Drug Discov 2009; 8:226-34; PMID:19247305; http://dx.doi.org/10.1038/nrd2804.
3. Shields RL, Namenuk AK, Hong K, Meng YG, Rae J, Briggs JB, et al. High resolution mapping of the binding site on human IgG1 for FcγRI, FcγRII, FcγRIII and FcRn and design of IgG1 variants with improved binding to the FcγR. J Biol Chem 2001; 276:6591-604; PMID:11096108; http://dx.doi.org/10.1074/jbc.M009483200.
4. Nimmerjahn F, Ravetch JV. Fcgamma receptors as regulators of immune responses. Nat Rev Immunol 2008; 8:34-47; PMID:18064051; http://dx.doi.org/10. 1038/nri2206.
5. Ferrara C, Grau S, Jäger C, Sondermann P, Brünker P, Waldhauer I, et al. Unique carbohydrate-carbohydrate interactions are required for high affinity binding between FcgammaRIII and antibodies lacking core fucose. Proc Natl Acad Sci USA 2011; 108:12669-74; PMID:21768335; http://dx.doi.org/10.1073/ pnas.1108455108.
6. Umaña P, Jean-Mairet J, Moudry R, Amstutz H, Bailey JE. Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity. Nat Biotechnol 1999; 17:176-80; PMID:10052355; http://dx.doi.org/10.1038/6179.
7. Kanda Y, Yamada T, Mori K, Okazaki A, Inoue M, Kitajima-Miyama K, et al. Comparison of biological activity among nonfucosylated therapeutic IgG1 antibodies with three different N-linked Fc oligosaccharides: the high-mannose, hybrid and complex types. Glycobiology 2007; 17:104-18; PMID:17012310; http://dx.doi.org/10.1093/glycob/cwl057.
8. Shields RL, Lai J, Keck RG, O'Connell LY, Hong K, Meng YG, et al. Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human FcgammaRIII and antibody-dependent cellular toxicity. J Biol Chem 2002; 277:26733-40; PMID:11986321; http://dx.doi.org/10.1074/jbc.M202069200.
9. Zhou Q, Shankara S, Roy A, Qiu H, Estes S, McVie- Wylie A, et al. Development of a simple and rapid method for producing non-fucosylated oligomannose containing antibodies with increased effector function. Biotechnol Bioeng 2008; 99:652-65; PMID:17680659; http://dx.doi.org/10.1002/bit.21598.
10. Wright A, Morrison SL. Effect of C2-associated carbohydrate structure on Ig effector function: studies with chimeric mouse-human IgG1 antibodies in glycosylation mutants of Chinese hamster ovary cells. J Immunol 1998; 160:3393-402; PMID:9531299.
11. Shinkawa T, Nakamura K, Yamane N, Shoji-Hosaka E, Kanda Y, Sakurada M, et al. The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. J Biol Chem 2003; 278:3466-73; PMID:12427744; http://dx.doi.org/10.1074/jbc.M210665200.
12. Mori K, Kuni-Kamochi R, Yamane-Ohnuki N, Wakitani M, Yamano K, Imai H, et al. Engineering Chinese hamster ovary cells to maximize effector function of produced antibodies using FUT8 siRNA. Biotechnol Bioeng 2004; 88:901-8; PMID:15515168; http://dx.doi.org/10.1002/bit.20326.
13. Li H, Sethuraman N, Stadheim TA, Zha D, Prinz B, Ballew N, et al. Optimization of humanized IgGs in glycoengineered Pichia pastoris. Nat Biotechnol 2006; 24:210-5; PMID:16429149; http://dx.doi.org/10.1038/nbt1178.
14. Hamilton SR, Bobrowicz P, Bobrowicz B, Davidson RC, Li H, Mitchell T, et al. Production of complex human glycoproteins in yeast. Science 2003; 301:1244-6; PMID:12947202; http://dx.doi.org/10.1126/science.1088166.
15. Stanley P. Lectin-resistant CHO cells: selection of new mutant phenotypes. Somatic Cell Genet 1983; 9:593-608; PMID:6623313; http://dx.doi.org/10.1007/BF01574260.
16. Wileman TE, Lennartz MR, Stahl PD. Identification of the macrophage mannose receptor as a 175-kDa membrane protein. Proc Natl Acad Sci USA 1986; 83:2501-5; PMID:3458213; http://dx.doi.org/10.1073/pnas.83.8.2501.
17. Schlesinger PH, Doebber TW, Mandell BF, White R, DeSchryver C, Rodman JS, et al. Plasma clearance of glycoproteins with terminal mannose and N-acetylglucosamine by liver non-parenchymal cells. Studies with beta-glucuronidase, N-acetyl-beta-D-glucosaminidase, ribonuclease B and agalacto-orosomucoid. Biochem J 1978; 176:103-9; PMID:728098.
18. Wright A, Morrison SL. Effect of altered CH2- associated carbohydrate structure on the functional properties and in vivo fate of chimeric mouse-human immunoglobulin G1. J Exp Med 1994; 180:1087-96; PMID:8064227; http://dx.doi.org/10.1084/jem.180.3.1087.
19. Chen W, Stanley P. Five Lec1 CHO cell mutants have distinct Mgat1 gene mutations that encode truncated N-acetylglucosaminyltransferase I. Glycobiology 2003; 13:43-50; PMID:12634323; http://dx.doi.org/10.1093/glycob/cwg003.
20. Wright A, Sato Y, Okada T, Chang KH, Endo T, Morrison SL. In vivo trafficking and catabolism of IgG1 antibodies with Fc associated carbohydrates of differing structure. Glycobiology 2000; 10:1347-55; PMID:11159927; http://dx.doi.org/10.1093/glycob/10.12.1347.
21. Chen X, Liu YD, Flynn GC. The effect of Fc glycan forms on human IgG2 antibody clearance in humans. Glycobiology 2009; 19:240-9; PMID:18974198; http://dx.doi.org/10.1093/glycob/cwn120.
22. Goetze AM, Liu YD, Zhang Z, Shah B, Lee E, Bondarenko PV, et al. High-mannose glycans on the Fc region of therapeutic IgG antibodies increase serum clearance in humans. Glycobiology 2011; 21:949-59; PMID:21421994; http://dx.doi.org/10.1093/glycob/cwr027.
23. Inoue T, Yoshida T, Ichishima E. Molecular cloning and nucleotide sequence of the 1,2-α-D-mannosidase gene, msdS, from Aspergillus saitoi and expression of the gene in yeast cells. Biochim Biophys Acta 1995; 1253:141-5; PMID:8519794; http://dx.doi.org/10.1016/0167-4838(95)00195-6.
24. Ichishima E, Taya N, Ikeguchi M, Chiba Y, Nakamura M, Kawabata C, et al. Molecular and enzymic properties of recombinant 1,2-α-mannosidase from Aspergillus saitoi overexpressed in Aspergillus oryzae cells. Biochem J 1999; 339:589-97; PMID:10215597; http://dx.doi.org/10.1042/0264-6021:3390589.
25. Pacis E, Yu M, Autsen J, Bayer R, Li F. Effects of cell culture conditions on antibody N-linked glycosylationwhat affects high mannose 5 glycoform. Biotechnol Bioeng 2011; 108:2348-58; PMID:21557201; http://dx.doi.org/10.1002/bit.23200.
26. Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med 2000; 6:443-6; PMID:10742152; http://dx.doi.org/10.1038/74704.
27. van der Kolk LE, Grillo-López AJ, Baars JW, Hack CE, van Oers MHJ. Complement activation plays a key role in the side-effects of rituximab treatment. Br J Haematol 2001; 115:807-11; PMID:11843813; http://dx.doi.org/10. 1046/j.1365-2141.2001.03166.x.
28. Clark EA, Ledbetter JA. How does B cell depletion therapy work, and how can it be improved? Ann Rheum Dis 2005; 64:77-80; PMID:16239394; http://dx.doi.org/10.1136/ard.2005.042507.
29. Correia IR. Stability of IgG isotypes in serum. MAbs 2010; 2:1-12; PMID:20065628; http://dx.doi.org/10.4161/mabs.2.3.11788.
30. Junttila TT, Parsons K, Olsson C, Lu Y, Xin Y, Theriault J, et al. Superior in vivo efficacy of afucosylated trastuzumab in the treatment of HER2-amplified breast cancer. Cancer Res 2010; 70:4481-9; PMID:20484044; http://dx.doi.org/10.1158/0008-5472.CAN-09-3704.
31. Lal A, Pang P, KalelkarS, Romero PA, Herscovics A, Moremen KW. Substrate specificities of recombinant murine Golgi α1,2-mannosidases IA and IB and comparison with endoplasmic reticulum and Golgi processing α1,2- mannosidases. Glycobiology 1998; 8:981-95; PMID:9719679; http://dx.doi.org/10. 1093/glycob/8.10.981.
32. Tremblay LO, Herscovics A. Characterization of a cDNA encoding a novel human Golgi α1,2-mannosidase (IC) involved in N-glycan biosynthesis. J BiolChem 2000; 275:31655-60; PMID:10915796; http://dx.doi.org/10.1074/jbc. M004935200.
33. Porwoll S, Fuchs H, Tauber R. Characterization of a soluble class I α-mannosidase in human serum. FEBS Lett 1999; 449:175-8; PMID:10338126; http://dx.doi.org/10.1016/S0014-5793(99)00422-6.
34. Gonzalez DS, Karaveg K, Vandersall-Nairn AS, Lal A, Moremen KW. Identification, expression and characterization of a cDNA encoding human endoplasmic reticulum mannosidase I, the enzyme that catalyzes the first mannose trimming step in mammalian Asn-linked oligosaccharide biosynthesis. J Biol Chem 1999; 274:21375-86; PMID:10409699; http://dx.doi.org/10.1074/jbc.274.30.21375.
35. Papac DI, Briggs JB, Chin ET, Jones AJS. A high-throughput microscale method to release N-linked oligosaccharides from glycoproteins for matrix-assisted laser desorption/ionization time-of-flight mass spectrometric analysis. Glycobiology 1998; 8:445-54; PMID:9597542; http://dx.doi.org/10.1093/ glycob/8.5.445.
36. Keck RG, Briggs JB, Jones AJS. Oligosaccharide release and MALDI-TOF MS analysis of N-linked carbohydrate structures from glycoproteins. Methods Mol Biol 2005; 308:381-96; PMID:16082050.
37. Idusogie EE, Presta LG, Gazzano-Santoro H, Totpal K, Wong PY, Ultsch M, et al. Mapping of the C1q binding site on rituxan, a chimeric antibody with a human IgG1 Fc. J Immunol 2000; 164:4178-84; PMID:10754313.
38. Hodoniczky J, Zheng YZ, James DC. Control of recombinant monoclonal antibody effector functions by Fc N-glycan remodeling in vitro. Biotechnol Prog 2005; 21:1644-52; PMID:16321047; http://dx.doi.org/10.1021/bp050228w.
39. Boyd PN, Lines AC, Patel AK. The effect of the removal of sialic acid, galactose and total carbohydrate on the functional activity of Campath-1H. Mol Immunol 1995; 32:1311-8; PMID:8643100; http://dx.doi.org/10.1016/0161-5890(95) 00118-2.